Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox (SPEED)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: April 25, 2008
Last updated: October 15, 2013
Last verified: October 2013

This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.

Condition Intervention Phase
Maxillary Sinusitis
Drug: Avelox (Moxifloxacin, BAY12-8039)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Time to bacteriological eradication in those who are microbiologically valid for S. pneumoniae, M. catarrhalis, and H. influenzae [ Time Frame: Days 1, 2, 3 of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Patient-reported symptom improvement using SNOT-16 questionnaire [ Time Frame: Up to End of Treatment (Day 10-13) ] [ Designated as safety issue: No ]
  • Clinical Response [ Time Frame: End of Treatment ] [ Designated as safety issue: Yes ]
  • Bacteriological Response [ Time Frame: End of Treatment ] [ Designated as safety issue: No ]
  • Activity Impairment Assessment questionnaire [ Time Frame: Up to End of Treatment (Day 10-13) ] [ Designated as safety issue: No ]
  • Incidence of Premature Termination [ Time Frame: Premature Termination ] [ Designated as safety issue: Yes ]
  • Adverse Events Collection [ Time Frame: Up to End of Treatment (Day 10-13) ] [ Designated as safety issue: Yes ]

Enrollment: 200
Study Start Date: June 2004
Study Completion Date: January 2005
Arms Assigned Interventions
Experimental: Arm 1 Drug: Avelox (Moxifloxacin, BAY12-8039)
Moxifloxacin 400 mg once orally daily


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of acute sinusitis with signs and symptoms present for >7 days but < 28 days as defined by A), radiographic, and B) clinical criteria, as follows:a. The presence of 1 or more of the following on a radiographic paranasal sinus film (Waters' view) or limited CT scan:** evidence of air-fluid levels** opacification. The presence of at least one major and one minor symptom as defined in the list below:** Major Symptoms*** Purulent anterior or posterior nasal discharge*** Unilateral moderate or severe facial pain or malar tenderness** Minor Symptoms*** Cough or frequent throat clearing*** Frontal headache*** Halitosis*** Fever (oral > 38.0°C/100.4°F, tympanic > 38.5°C/101.2°F)*** Purulent secretions obtained via middle meatus secretion sampling using nasal endoscopic technique; the specimen sent for Gram stain, culture and susceptibility testing prior to initiation of antimicrobial therapy

Exclusion Criteria:

  • History of chronic sinusitis defined as greater than four weeks of continuous symptoms (patients with history of sinus surgery may be included; patients with recurrent sinusitis may be included)
  • Known bacteremia, meningitis or infection infiltrating the tissues neighboring the sinuses- Received systemic antibacterial therapy likely to be effective in sinusitis for more than 24 hours within 7 days of enrollment- A requirement for concomitant systemic antibacterial therapy with agents other than those specified in this protocol- Known immunodeficiency diseases including AIDS (CD4 <200)- On topical nasal or systemic corticosteroids, unless they have been on a stable dose for > 4 weeks prior to enrollment- History of allergy to quinolone antibiotics or related compounds- Pregnant or breast feeding- Of childbearing potential in whom pregnancy cannot be excluded by a negative pregnancy test and who are not using reliable barrier method of contraception
  • Received an investigational drug in the past 30 days- Unable to take oral medication- Known to have congenital or sporadic syndromes of QTc prolongation or receiving concomitant medication reported to increase the QTc interval (e.g. amiodarone, sotalol, disopyramide, quinidine, procainamide, terfenadine)
  • End stage liver cirrhosis (class Child-Pugh C)- Severe renal impairment requiring dialysis
  • Previous history of tendinopathy associated with quinolones- Any symptoms that suggest that the patient's current illness is allergic rhinitis (e.g., repetitive sneezing, itchy nose or eyes, provocation by an allergen) and not acute bacterial sinusitis
  • Diagnosis of rapidly fatal illness with a life expectance of less than 6 months- Previously enrolled in this clinical study- Uncorrected hypokalaemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00668304

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States, 35206
Hoover, Alabama, United States, 35216-5453
United States, Arkansas
Jonesboro, Arkansas, United States, 72401
Searcy, Arkansas, United States, 72143
United States, California
Fresno, California, United States, 93720
Riverside, California, United States, 92506
San Francisco, California, United States, 94102
United States, Colorado
Colorado Springs, Colorado, United States, 80909
Longmont, Colorado, United States, 80501
United States, Connecticut
Bridgeport, Connecticut, United States, 06606
United States, Florida
DeLand, Florida, United States, 32720-2560
United States, Louisiana
Shreveport, Louisiana, United States, 71105
United States, Michigan
Detroit, Michigan, United States, 48202
United States, New York
North Massapequa, New York, United States, 11758
Rochester, New York, United States, 14618
United States, Ohio
Columbus, Ohio, United States, 43235
United States, Oklahoma
Oklahoma City, Oklahoma, United States, 73120
Yukon, Oklahoma, United States, 73099
United States, Oregon
Lake Oswego, Oregon, United States, 97035
United States, Pennsylvania
Harrisburg, Pennsylvania, United States, 17110
United States, South Carolina
Greenville, South Carolina, United States, 29607
Orangeburg, South Carolina, United States, 29118
United States, Tennessee
Jackson, Tennessee, United States, 38301
United States, Texas
Carrollton, Texas, United States, 75010
United States, Utah
Salt Lake City, Utah, United States, 84102
United States, Virginia
Charlottesville, Virginia, United States, 22902
Richmond, Virginia, United States, 23229
Winchester, Virginia, United States, 22601
United States, Washington
Spokane, Washington, United States, 99202-1334
Florencio Varela, Buenos Aires, Argentina, 1888
Buenos Aires, Capital Federal, Argentina, 1416
Buenos Aires, Capital Federal, Argentina, C1280AEB
Rosario, Santa Fé, Argentina, 2000
San Miguel de Tucumán, Tucumán, Argentina, 4000
Córdoba, Argentina, 5000
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Bayer Identifier: NCT00668304     History of Changes
Other Study ID Numbers: 100569
Study First Received: April 25, 2008
Last Updated: October 15, 2013
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
United States: Institutional Review Board

Keywords provided by Bayer:

Additional relevant MeSH terms:
Maxillary Sinusitis
Nose Diseases
Otorhinolaryngologic Diseases
Paranasal Sinus Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on November 27, 2014